251 related articles for article (PubMed ID: 35485450)
1. Real-world efficacy of lutetium peptide receptor radionuclide therapy in patients with neuroendocrine tumours.
Almeamar H; Cullen L; Murphy DJ; Crowley RK; Toumpanakis C; Welin S; O'Shea D; O'Toole D
J Neuroendocrinol; 2022 Jun; 34(6):e13138. PubMed ID: 35485450
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea.
Shin Y; Moon BH; Ryoo BY; Chang HM; Kim KP; Hong YS; Kim TW; Ryu JS; Kim YI; Yoo C
Target Oncol; 2024 Jan; 19(1):41-49. PubMed ID: 38108953
[TBL] [Abstract][Full Text] [Related]
3. Peptide receptor radionuclide therapy (PRRT) in metastatic neuroendocrine tumors of unknown primary (CUP-NETs).
Baum RP; Wang P; Jakobsson V; Zhao T; Schuchardt C; Khong PL; Zhang J
Theranostics; 2024; 14(1):133-142. PubMed ID: 38164147
[No Abstract] [Full Text] [Related]
4. Efficacy and tolerability of peptide receptor radionuclide therapy (PRRT) in advanced metastatic bronchial neuroendocrine tumours (NETs).
Mirvis E; Toumpanakis C; Mandair D; Gnanasegaran G; Caplin M; Navalkissoor S
Lung Cancer; 2020 Dec; 150():70-75. PubMed ID: 33075738
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcome of indigenous
Sitani K; Parghane RV; Talole S; Basu S
Br J Radiol; 2021 Jan; 94(1117):20201041. PubMed ID: 33095671
[TBL] [Abstract][Full Text] [Related]
6. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
[TBL] [Abstract][Full Text] [Related]
7. Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis.
Thang SP; Lung MS; Kong G; Hofman MS; Callahan J; Michael M; Hicks RJ
Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):262-277. PubMed ID: 28894897
[TBL] [Abstract][Full Text] [Related]
8. Long-term results of PRRT in advanced bronchopulmonary carcinoid.
Mariniello A; Bodei L; Tinelli C; Baio SM; Gilardi L; Colandrea M; Papi S; Valmadre G; Fazio N; Galetta D; Paganelli G; Grana CM
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):441-52. PubMed ID: 26392198
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of peptide receptor radionuclide therapy with
Jiang Y; Liu Q; Wang G; Sui H; Wang R; Wang J; Zhang J; Zhu Z; Chen X
Theranostics; 2022; 12(15):6437-6445. PubMed ID: 36185603
[No Abstract] [Full Text] [Related]
10. Peptide receptor radiotherapy re-treatment in patients with progressive neuroendocrine tumors: A systematic review and meta-analysis.
Strosberg J; Leeuwenkamp O; Siddiqui MK
Cancer Treat Rev; 2021 Feb; 93():102141. PubMed ID: 33418096
[TBL] [Abstract][Full Text] [Related]
11. Highly favourable outcomes with peptide receptor radionuclide therapy (PRRT) for metastatic rectal neuroendocrine neoplasia (NEN).
Kong G; Grozinsky-Glasberg S; Hofman MS; Akhurst T; Meirovitz A; Maimon O; Krausz Y; Godefroy J; Michael M; Gross DJ; Hicks RJ
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):718-727. PubMed ID: 30343432
[TBL] [Abstract][Full Text] [Related]
12. Single centre retrospective review of outcome of
Alsadik S; Gnanasegaran G; Chen L; Quigley AM; Mandair D; Toumpanakis C; Caplin M; Navalkissoor S
J Neuroendocrinol; 2022 Nov; 34(11):e13210. PubMed ID: 36399420
[TBL] [Abstract][Full Text] [Related]
13. Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients receiving Concomitant
Ballal S; Yadav MP; Tripathi M; Sahoo RK; Bal C
J Nucl Med; 2022 Jul; ():. PubMed ID: 35863893
[No Abstract] [Full Text] [Related]
14. Salvage peptide receptor radionuclide therapy with [
van der Zwan WA; Brabander T; Kam BLR; Teunissen JJM; Feelders RA; Hofland J; Krenning EP; de Herder WW
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):704-717. PubMed ID: 30267116
[TBL] [Abstract][Full Text] [Related]
15. The evolution of PRRT for the treatment of neuroendocrine tumors; What comes next?
Harris PE; Zhernosekov K
Front Endocrinol (Lausanne); 2022; 13():941832. PubMed ID: 36387893
[TBL] [Abstract][Full Text] [Related]
16. In patients with well-differentiated neuroendocrine tumours, there is no apparent benefit of somatostatin analogues after disease control by peptide receptor radionuclide therapy.
Syguła A; Ledwon A; Hasse-Lazar K; Jurecka-Lubieniecka B; Michalik B; Paliczka-Cieślik E; Zeman M; Chmielik E; Sczasny J; Jarzab B; Handkiewicz-Junak D
Eur J Nucl Med Mol Imaging; 2022 Sep; 49(11):3841-3851. PubMed ID: 35503379
[TBL] [Abstract][Full Text] [Related]
17. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
Parghane RV; Talole S; Prabhash K; Basu S
Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500
[TBL] [Abstract][Full Text] [Related]
18. Peptide Receptor Radionuclide Therapy in Grade 3 Neuroendocrine Neoplasms: Safety and Survival Analysis in 69 Patients.
Zhang J; Kulkarni HR; Singh A; Niepsch K; Müller D; Baum RP
J Nucl Med; 2019 Mar; 60(3):377-385. PubMed ID: 30115686
[TBL] [Abstract][Full Text] [Related]
19. Peptide Receptor Radionuclide Therapy With 177Lu-Octreotate in Patients With Somatostatin Receptor Expressing Neuroendocrine Tumors: Six Years' Assessment.
Hamiditabar M; Ali M; Roys J; Wolin EM; OʼDorisio TM; Ranganathan D; Tworowska I; Strosberg JR; Delpassand ES
Clin Nucl Med; 2017 Jun; 42(6):436-443. PubMed ID: 28263217
[TBL] [Abstract][Full Text] [Related]
20. Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study.
Carlsen EA; Fazio N; Granberg D; Grozinsky-Glasberg S; Ahmadzadehfar H; Grana CM; Zandee WT; Cwikla J; Walter MA; Oturai PS; Rinke A; Weaver A; Frilling A; Gritti S; Arveschoug AK; Meirovitz A; Knigge U; Sorbye H
Endocr Relat Cancer; 2019 Feb; 26(2):227-239. PubMed ID: 30540557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]